

Preferred Drug List (PDL) Changes Effective March 12, 2009

The Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met on Dec. 11, 2008. The actions taken by the committee regarding the Nevada Medicaid Preferred Drug List (PDL) are listed below.

The complete PDL is posted on the ["Preferred Drug List"](#) webpage.

All changes are effective March 12, 2009:

Drug Class	Drugs Added	Drugs Removed	Drugs Reviewed But Not Added
Central Nervous System: ADHD/Stimulants	None	Metadate CD®	None
Platelet Aggregation Inhibitors (New PDL Class)	Aggrenox® Aspirin Dipyridamole Plavix®	None	Ticlopidine
Alzheimer's Agents (New PDL Class)	Aricept® Exelon® Capsules, Patch, and Solution Namenda®		Aricept ODT® Cognex® Razadyne®
Antiparkinson's Agents: Non-ergot Dopamine Agonists (New PDL Class)	Mirapex® Requip XL® Ropinirole	None	None
Cardiovascular: Antihyperlipidemics: Triglyceride Lowering Agents	None	None	Lovaza®